| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Mite
|
|---|---|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
After placing 50 mg samples of Rhizoglyphus echinopus (Fumouze and Robin) in glass vials coated with 0.53 μg of radiocarbon-labeled propargite for 1 hour, approximately 12% (1.27 μg/g) of the acaricide was transferred into the mites. Mites treated with propargite were preserved in storage bottles, and their metabolic extent was assessed at 6, 12, 24, and 48 hours. The in vivo radiocarbon content ranged from 14.8% to 17.4% of the dose, and was approximately evenly distributed between the mite extract and mite residues. When expressed as a percentage of total recovered radiocarbon, the propargite content in the internal extract decreased from 5.9% at 6 hours to 2.5% at 48 hours; when expressed as a relative percentage of radiocarbon in the internal extract, the propargite content decreased from 61.5% at 6 hours to 29.8% at 48 hours. Therefore, propargite was slowly degraded by the mites. The metabolites 4-tert-butylphenol and 2-(4-tert-butylphenoxy)cyclohexanol (ethylene glycol ether) were present in low concentrations (<0.5%). In vitro experiments showed that M. bulgaricus homogenate could degrade propargyl, with the supernatant after 12,000 centrifugations exhibiting approximately four times the activity of the corresponding precipitate. Exogenous NADPH and glutathione significantly enhanced the degradation of propargyl by the supernatant. However, in the presence of glutathione, not all degradation was enzymatic. When the acaricide was incubated with cofactors in a buffer solution containing no mite supernatant, approximately 15% of the propargyl dicarboxylate was converted to 4-tert-butylphenol. The in vitro degradation products of propargyl dicarboxylate mainly consisted of unidentified polar metabolites, but also contained small amounts of 4-tert-butylphenol and ethylene glycol ether. |
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) = 890 mg/m3 Non-human Toxicity Values LD50 Rabbit Acute Dermal Administration >2000 mg/kg LD50 Rat (Female) Acute Oral Administration 2947 mg/kg LD50 Rat (Male) Acute Oral Administration 2639 mg/kg LD50 Rat (Male and Female) Acute Oral Administration 2800 mg/kg For more complete non-human toxicity data on propyne (8 items), please visit the HSDB records page. |
| References |
[1]. Ting Zhou, et al. A hPSC-based Platform to Discover Gene-Environment Interactions That Impact Human β-cell and Dopamine Neuron Survival. Nat Commun. 2018 Nov 16;9(1):4815.
|
| Additional Infomation |
According to the U.S. Environmental Protection Agency (EPA), propargylene may be carcinogenic and developmentally toxic. Proargylene is a dark liquid, available as a wettable powder or water emulsion. It can cause illness through inhalation, skin absorption, and/or ingestion. Its primary hazard lies in its environmental threat. Immediate measures should be taken to limit its spread into the environment. Because it is a liquid, it easily seeps into soil, contaminating groundwater and nearby streams. It is used as an insecticide, being almost insoluble in water (10.5 mg/L). It is also used as an acaricide. Proargylene is a sulfite ester and terminal alkyne compound. It is a sulfite acaricide. Proargyl ester (IUPAC name: 2-(4-tert-butylphenoxy)cyclohexylprop-2-yne-1-sulfonate, trade names: Omete and Commet) is an insecticide (acaricide) used to kill mites. Symptoms of contact and poisoning include eye and skin irritation and allergic reactions. It is highly toxic to amphibians, fish, and zooplankton, and has potential carcinogenicity.
|
| Molecular Formula |
C19H26O4S
|
|---|---|
| Molecular Weight |
350.47234
|
| Exact Mass |
350.155
|
| CAS # |
2312-35-8
|
| PubChem CID |
4936
|
| Appearance |
Brownish-yellow, oily viscous liquid (tech.)
Light to dark brown viscous liquid |
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
450.7±45.0 °C at 760 mmHg
|
| Flash Point |
226.4±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.561
|
| LogP |
4.81
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
24
|
| Complexity |
454
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C#CCOS(=O)OC1CCCCC1OC2=CC=C(C=C2)C(C)(C)C
|
| InChi Key |
ZYHMJXZULPZUED-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H26O4S/c1-5-14-21-24(20)23-18-9-7-6-8-17(18)22-16-12-10-15(11-13-16)19(2,3)4/h1,10-13,17-18H,6-9,14H2,2-4H3
|
| Chemical Name |
[2-(4-tert-butylphenoxy)cyclohexyl] prop-2-ynyl sulfite
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8533 mL | 14.2666 mL | 28.5331 mL | |
| 5 mM | 0.5707 mL | 2.8533 mL | 5.7066 mL | |
| 10 mM | 0.2853 mL | 1.4267 mL | 2.8533 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
